13F reference period
Q2 2026
Security Snapshot
IONIS PHARMACEUTICALS INC - COMMON STOCK (IONS) Institutional Ownership
CUSIP: 462222100
13F Institutional Holders and Ownership History from Q4 2015 to Q3 2026
Institutions Reporting
514
Shares (Excl. Options)
179,714,934
Price
$79.29
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- IONS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 179,714,934
- Total 13F value
- $14,261,324,745
- Portfolio coverage rank
- 0.01%
- Share change
- +7,052,489
- Value change
- +$562,057,010
- Number of holders
- 514
- Shares outstanding
- 166,460,189
- SEC-reported price per share
- $44.65
- Insider filing price
- $44.65
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- IONS - IONIS PHARMACEUTICALS INC - COMMON STOCK is tracked under CUSIP 462222100.
- 514 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 494 to 514 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $12,956,101,841 to $14,261,324,745.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 514 institutions filings for Q2 2026.
Security key
462222100
13F reference period
Q2 2026
13F holders
514
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
IONS full holder history
IONIS PHARMACEUTICALS INC SEC filings
IONIS PHARMACEUTICALS INC company facts
IONIS PHARMACEUTICALS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 462222100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
IONS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Capital World Investors | 13% | +15% | $1,592,579,358 | +$242,428,512 | 21,186,369 | +18% | Capital World Investors | 31 Mar 2026 |
| BlackRock, Inc. | 5.7% | $269,638,216 | 9,066,517 | BlackRock, Inc. | 31 Mar 2025 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5% | $626,605,926 | 8,344,732 | Vanguard Capital Management | 31 Mar 2026 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 4.3% | $284,413,950 | 6,879,873 | Wellington Management Group LLP | 30 Jun 2025 | |||
| T. Rowe Price Investment Management, Inc. | 3.7% | -32% | $462,974,060 | -$221,675,729 | 6,159,027 | -32% | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 |
As of 30 Jun 2026, 514 institutional investors reported holding 179,714,934 shares of IONIS PHARMACEUTICALS INC - COMMON STOCK (IONS). This represents 108% of the company’s total 166,460,189 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
80%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 24,631,956 | +0.31% | 0.08% | $1,953,067,764 |
| Capital World Investors | 13% | 21,669,226 | +2.3% | 0.2% | $1,718,152,930 |
| BlackRock, Inc. | 6.4% | 10,704,660 | +2.5% | 0.01% | $848,772,532 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.7% | 7,859,529 | +0.65% | 0.03% | $623,182,054 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.6% | 7,651,415 | +20% | 0.1% | $606,680,694 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 7,211,497 | +1.3% | 0.01% | $571,799,597 |
| TWO SIGMA INVESTMENTS, LP | 3.8% | 6,252,342 | +6.7% | 0.37% | $495,748,197 |
| ROYAL BANK OF CANADA | 3.7% | 6,182,479 | +63% | 0.08% | $490,209,000 |
| STATE STREET CORP | 2.6% | 4,334,848 | +8.5% | 0.01% | $343,710,098 |
| T. Rowe Price Investment Management, Inc. | 2.4% | 3,959,372 | -36% | 0.21% | $313,939,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 3,584,024 | -10% | 0.02% | $294,752,810 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.9% | 3,184,500 | +5.3% | 0.03% | $252,500,000 |
| JPMORGAN CHASE & CO | 1.6% | 2,671,717 | +13% | 0.01% | $216,198,792 |
| Artisan Partners Limited Partnership | 1.6% | 2,640,024 | +28% | 0.34% | $209,327,536 |
| Tweedy, Browne Co LLC | 1.4% | 2,280,311 | +0.21% | 14% | $180,805,859 |
| Deep Track Capital, LP | 1.3% | 2,200,000 | +13% | 2.6% | $174,438,000 |
| GOLDMAN SACHS GROUP INC | 1.3% | 2,109,945 | +24% | 0.02% | $167,297,540 |
| BAKER BROS. ADVISORS LP | 1.2% | 2,047,727 | 0% | 0.81% | $162,364,274 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.2% | 1,979,669 | 0% | 1.6% | $156,967,955 |
| AMERICAN CENTURY COMPANIES INC | 1.2% | 1,947,076 | +17% | 0.07% | $154,383,816 |
| FRANKLIN RESOURCES INC | 0.98% | 1,623,377 | +3.1% | 0.03% | $128,717,601 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.96% | 1,605,054 | +1.4% | 0.02% | $127,264,731 |
| BARCLAYS PLC | 0.96% | 1,603,136 | +453% | 0.04% | $127,112,653 |
| Pictet Asset Management Holding SA | 0.96% | 1,596,998 | +11% | 0.12% | $126,981,913 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 0.87% | 1,454,672 | -1.4% | 0.02% | $115,340,943 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
44
Headline period
Q2 2026
Rows shown
1-25 of 44
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 811,614 | $36,222,228 | -$22,261,950 | $44.65 | 60 |
| 2026 Q2 | 179,714,934 | $14,261,324,745 | +$562,057,010 | $79.29 | 514 |
| 2026 Q1 | 172,546,624 | $12,956,101,841 | +$156,994,656 | $75.09 | 494 |
| 2025 Q4 | 170,226,720 | $13,463,922,363 | +$164,534,797 | $79.11 | 491 |
| 2025 Q3 | 168,163,078 | $11,001,578,263 | +$32,287,787 | $65.42 | 433 |
| 2025 Q2 | 168,850,675 | $6,672,661,270 | +$162,663,034 | $39.51 | 360 |
| 2025 Q1 | 165,860,888 | $5,004,903,523 | +$131,542,151 | $30.17 | 340 |
| 2024 Q4 | 160,366,928 | $5,606,135,985 | +$73,787,817 | $34.96 | 348 |
| 2024 Q3 | 157,127,745 | $6,297,681,566 | +$509,606,602 | $40.06 | 348 |
| 2024 Q2 | 143,207,231 | $6,823,555,846 | +$50,229,849 | $47.66 | 353 |
| 2024 Q1 | 141,857,166 | $6,150,040,836 | -$14,832,123 | $43.35 | 355 |
| 2023 Q4 | 142,480,404 | $7,209,128,718 | +$87,362,106 | $50.59 | 360 |
| 2023 Q3 | 139,863,021 | $6,344,228,254 | +$143,056,679 | $45.36 | 307 |
| 2023 Q2 | 136,544,584 | $5,601,663,585 | +$217,908,412 | $41.03 | 299 |
| 2023 Q1 | 131,377,079 | $4,693,255,222 | +$26,766,918 | $35.74 | 307 |
| 2022 Q4 | 130,693,455 | $4,936,957,475 | +$160,016,480 | $37.77 | 333 |
| 2022 Q3 | 126,410,568 | $5,587,594,025 | -$405,286,321 | $44.23 | 335 |
| 2022 Q2 | 124,531,298 | $4,607,099,903 | +$7,650,768 | $37.02 | 329 |
| 2022 Q1 | 124,797,488 | $4,621,087,277 | +$93,759,462 | $37.04 | 314 |
| 2021 Q4 | 123,208,578 | $3,749,220,496 | +$12,496,745 | $30.43 | 321 |
| 2021 Q3 | 121,685,400 | $4,081,694,378 | -$99,758,435 | $33.54 | 306 |
| 2021 Q2 | 124,355,726 | $4,958,884,573 | +$71,970,644 | $39.89 | 321 |
| 2021 Q1 | 123,194,653 | $5,537,925,756 | +$78,758,790 | $44.96 | 347 |
| 2020 Q4 | 120,098,693 | $6,792,775,467 | +$105,597,041 | $56.54 | 366 |
| 2020 Q3 | 118,507,239 | $5,623,405,509 | -$83,647,855 | $47.45 | 353 |